Skip to main content

Equibles does not estimate personal net worth.

About Stuart Poulton

Karyopharm Therapeutics Inc. reported in an 8-K filed July 28, 2022 that Stuart Poulton was appointed Executive Vice President, Chief Development Officer, effective July 27, 2022. The proxy statement of Karyopharm Therapeutics Inc. reports total compensation of $1,399,580 for Stuart Poulton in fiscal 2025, including a base salary of $500,135. Disclosed compensation is on record for 4 fiscal years. Karyopharm Therapeutics Inc. is classified in the Biotechnology industry within the Healthcare sector. Other leadership on record at Karyopharm Therapeutics Inc. includes Richard Paulson (CEO and Board Member), Senior Clinical (CEO), Michael Mano (General Counsel) and 7 others.

“Stuart Poulton, who has served as the Company's Senior Vice President, Strategy and Portfolio Management since February 2022, has been promoted to Executive Vice President, Chief Development Officer, effective July 27, 2022.”
Karyopharm Therapeutics Inc. Form 8-K, filed July 28, 2022 · Read the filing

Affiliation history

Company network

Leadership on record at Karyopharm Therapeutics Inc.

Executive compensation

Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.

Fiscal year Company Salary Total
2025 Karyopharm Therapeutics Inc. (KPTIQ) $500,135 $1,399,580
2024 Karyopharm Therapeutics Inc. (KPTIQ) — —
2023 Karyopharm Therapeutics Inc. (KPTIQ) $477,000 $1,109,115
2022 Karyopharm Therapeutics Inc. (KPTIQ) $373,910 $1,795,247

Recent activity